This article is more than 5 years old. Information may no longer be current.

TACTICS: Framing effects intervention lowered LDL in diabetes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — A framing effects intervention has been shown to lower LDL levels and improve LDL control in patients with type 2 diabetes, according to the results of a randomized trial presented here at the ADA Scientific Sessions.

The Targeting Adherence to Cholesterol-lowering Treatment to Improve Control Study (TACTICS) aimed to determine whether tailored interventions would improve adherence in patients with diabetes and uncontrolled LDL (LDL ≥ 100 mg/dL). A total of 247 veterans with type 2 diabetes and hyperlipidemia were randomly assigned to a stage-matched intervention (n=82), a framing effects intervention (n=84) or attention placebo (n=81). Six-month follow-up data were available for 222 participants (framing effects intervention, n=75; stage-matched intervention, 73; attention placebo, n=74). The interventions were tailored to diet, exercise and medications, and all participants received phone counseling sessions each month for 6 months.

At baseline, median LDL levels were 105 mg/dL for the framing effects intervention group, 112 mg/dL for the stage-matched intervention group and 111 mg/dL for the attention placebo group. LDL control was 42.17%, 28.75% and 25.00%, respectively.

At 6 months, median LDL levels were 92 mg/dL for participants receiving the framing effects intervention (P=.005) and 103 mg/dL for those receiving the stage-matched intervention (P=.46) vs. 106 mg/dL those receiving placebo. LDL control was 62.67% in the framing effects group (P=.01) and 46.58% in the stage-matched intervention group (P=.46) vs. 40.54% in the placebo, according to unadjusted analyses.

After controlling for baseline LDL and BMI, results from a linear regression model associated the framing effects intervention with a –10.80 mg/dL (95% CI, –20.5 to –1.1) change in LDL at 6 months whereas the stage-matched intervention was associated with a –4.35 mg/dL (95% CI, –15.0 to 6.3) change. Results also linked the framing effects intervention with an OR of 3.8 (95% CI, 1.6-9.0) and the stage-matched intervention with an OR of 2.1 (95% CI, 1.0-3.4).

“This [framing effects intervention] may be a potent facilitator for reaching lipid lowering goals in patients with type 2 diabetes and hyperlipidemia,” researchers wrote in the abstract.

For more information:

Rodriguez MA. 29-LB. Presented at: ADA Scientific Sessions; June 21-25, 2013; Chicago.